C4X Discovery Holdings plc is a drug discovery company. The Company has a portfolio ranges from early-stage target opportunities to late-stage drug discovery programs. It has a portfolio of five internal programs and three commercially partnered programs, one of which is in clinical trials. Its internal portfolio is focused on immuno-inflammatory diseases with its lead a4B7 inhibitor program. Its pipeline products include MALT-1 Inhibitor, a4B7 Integrin Inhibitor, Orexin-1, IL-17A Inhibitor, NRF-2 Activator, and others. Its target identification platform (Taxonomy3) is used to analyze complex genetic datasets to identify and characterize drug target candidates. Taxonomy3 offers the potential for patient stratification in clinical trials, ensuring patient targeting and the potential for rescuing failed clinical trials or for drug repurposing. PatientSeek is its new platform that applies the mathematical approach of Taxonomy3 to stratify patients for treatments based on their genetics.